{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:06:13Z","timestamp":1791237973913,"version":"4.1.0"},"reference-count":49,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BTT"],"DOI":"10.2147\/btt.s252578","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T21:00:16Z","timestamp":1613422816000},"page":"39-51","source":"Crossref","is-referenced-by-count":83,"title":["Biologic Treatments of Psoriasis: An Update for the Clinician"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Nicholas","family":"Brownstone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Hadeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7883-6439","authenticated-orcid":true,"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref2","first-page":"S2","volume":"33","author":"Alwan","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1627","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.jaad.2005.11.1088","volume":"54","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa030409","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1111\/jdv.15793","volume":"33","author":"Elewski","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref8","unstructured":"Wu JJ, Abramovits W, Valdecantos WC, et al. 10-year interim results from the ESPRIT registry: real-world safety, effectiveness, and patient-reported outcomes of adalimumab for moderate-to-severe psoriasis. Poster presented at the: 28th European Academy of Dermatology and Venereology (EADV) Congress; October 2019; Madrid, Spain; 2020."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(14)60602-8","author":"Mahadevan","year":"2014","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000582","author":"Van Der Heijde","year":"2018","journal-title":"RMD Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.012","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211384","author":"Clowse","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1067\/mjd.2003.10","volume":"48","author":"Gottlieb","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/j.0022-202X.2004.23448.x","volume":"123","author":"Kauffman","year":"2004","journal-title":"J Investig Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jaad.2019.05.007","volume":"81","author":"Kimmel","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.36849\/JDD.2020.5138","volume":"19","author":"Lebwohl","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/2475530319842174","volume":"4","author":"Feldman","year":"2019","journal-title":"JPPA"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"AB39","DOI":"10.1016\/j.jaad.2019.06.179","volume":"81","author":"Jia","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/2475530320925067","volume":"5","author":"Brownstone","year":"2020","journal-title":"JPPA"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221923","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19262","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjd.18331","volume":"182","author":"Gottlieb","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","volume":"8","author":"Bagel","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjd.19147","volume":"183","author":"Paller","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Ixekizumab vs. Guselkuamb: 24 week clinical responses and 4-week gene expression data. Oral presentation presented at the: Maui Derm; June 2020; Virtual Congress; 2020.","DOI":"10.1016\/j.jid.2020.05.033"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/annrheumdis-2020-eular.4615","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref32","first-page":"200","volume":"17","author":"Shear","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13671-020-00286-2","volume":"9","author":"Blauvelt","year":"2020","journal-title":"Curr Derm Rep"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Reich K, Papp K, Blauvelt A, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE VIVID, a 52-week phase 3, randomized, double-blinded, ustekinumab- and placebo\u2011controlled study. Oral presentation presented at the: American Academy of Dermatology (AAD); March 2020; Virtual Conference; 2020.","DOI":"10.25251\/skin.4.supp.82"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Gordon K, Foley P, Krueger JG, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis: results from BE READY, a 56-week phase 3, randomized, double-blinded, placebo-controlled study with randomized withdrawal. Oral presentation presented at the: American Academy of Dermatology (AAD); March 2020; Virtual Conference; 2020","DOI":"10.25251\/skin.4.supp.83"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"AB164","DOI":"10.1016\/j.jaad.2017.04.637","volume":"76","author":"Papp","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref38","unstructured":"Tha\u00e7i D, Iversen L, Pau-Charles I, Rozzo S, Blauvelt A, Reich K. Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were responders at week 28: pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials. Oral presentation presented at the: 27th European Academy of Dermatology and Venereology (EADV) Congress; September 2018; Paris, France; 2018."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"s40","DOI":"10.25251\/skin.4.supp.40","volume":"4","author":"Cantrell","year":"2020","journal-title":"J Skin"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341","author":"Warren","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref44","unstructured":"Gordon KB, Bachelez H, Blauvelt A, et al. Pooled long-term safety analysis of risankizumab in patients with moderate to severe psoriasis. Poster presented at the: 78th Annual Meeting of the American Academy of Dermatology; March 2020; Virtual Conference; 2020."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjd.17628","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Bissonnette R, Maari C, Menter MA, et al. Efficacy and safety of mirikizumab in patients with moderate-to-severe plaque psoriasis: 104-week results from a randomized phase 2 study. Poster presented at the: American Academy of Dermatology (AAD); March 2020; Virtual Conference; 2020.","DOI":"10.1016\/j.jaad.2020.06.677"}],"container-title":["Biologics: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=66653","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=66653","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T21:01:01Z","timestamp":1613422861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/biologic-treatments-of-psoriasis-an-update-for-the-clinician-peer-reviewed-article-BTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":49,"URL":"https:\/\/doi.org\/10.2147\/btt.s252578","relation":{},"ISSN":["1177-5491"],"issn-type":[{"value":"1177-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}